| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15405 R63476 |
Lee - Alprazolam, 2022 | Apgar score at 5 min (7 or less) | 1st trimester excluded | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Not specified |
3.68 [0.85;16.00] excluded (exposition period) |
3/61 6/461 | 9 | 61 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15319 R63024 |
Freeman - BZDs, 2018 | Low 5-minute Apgar (< 7) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 4.91 [0.69;34.96] | 6/108 12/378 | 18 | 108 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15312 R63003 |
Christensen - Clonazepam (Mixed indications), 2015 | Low Apgar score (≤ 7) at 5 min | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: No (among antiseizure medications) | 1.47 [0.62;3.51] | 5/260 8,797/674,115 | 8,802 | 260 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15587 R64172 |
Källén - BZDs, 2013 | Low Apgar score (< 7 at 5min) | 2nd and/or 3rd trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Not specified | 2.18 [1.93;2.48] | 257/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15320 R63035 |
Calderon-Margalit - BZDs, 2009 | APGAR Score at 5 minute <7 | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) | 3.87 [1.53;9.76] | 7/85 37/2,493 | 44 | 85 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 2.19 [1.94;2.48] | 8,864 | 453 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Mixed indications;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded